Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

CDMO Space In Focus As Piramal Mulls Sale

As the Indian business conglomerate Piramal considers the sale of its contract development and manufacturing organization (CDMO), some experts say that more CDMO players could potentially join the sale line up in a fragmented sector but one that’s in demand.
Commercial Deals

Data Integrity And The Iceberg Concern

US FDA official outlines a number of issues around data integrity lapses, including how they trigger concern around all records of a non-compliant firm and that certain factors, including the limited oversight of sponsors over CMOs, could potentially be linked with data integrity problems.
Manufacturing India

Can Lilly's Olumiant Prickle Xeljanz In India?

Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
India Commercial

India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
Regulation Drug Safety

Cipla Rejigs Deck As Global Head Of Operations Moves On

Cipla’s global head (operations) Raju Subramanyam is leaving the firm to pursue his own ambitions. The exit has resulted in an interesting portfolio rejig at the Mumbai-based firm, known for its generally clear manufacturing compliance record.

Leadership Appointments

More Manufacturing Rationalization On The Cards At Dr Reddy’s?

Dr Reddy’s quest to emerge as an “internationally cost-competitive and more nimble organization” is expected to entail further rationalization of the firm’s manufacturing network. The company may put on the block a formulations site in India, if the buzz on deal street is to be believed.
Commercial Strategy
See All
Advertisement
UsernamePublicRestriction

Register